Neoadjuvant and Adjuvant Chemotherapy in Osteosarcoma (The Experience of HORC in the Shariati Hospital)
: Osteosarcoma is the most common bone sarcoma, and the third most common malignancy in children and adolescents. Before 1970, amputation was the sole treatment. Eighty percent of patients died from metastatic diseases, most commonly in the lungs. Over the past three decades, effective neoadjuvant (...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Tehran University of Medical Sciences
2004-07-01
|
| Series: | International Journal of Hematology-Oncology and Stem Cell Research |
| Subjects: | |
| Online Access: | http://journals.tums.ac.ir/PdfMed.aspx?pdf_med=/upload_files/pdf/4479.pdf&manuscript_id=4479 |
| _version_ | 1797760938260037632 |
|---|---|
| author | Alimoghadam K Ghavamzadeh A Jafari M. Sami Hagialilo S Jahani M khodabandeh A Eghbal L Gholibekian S |
| author_facet | Alimoghadam K Ghavamzadeh A Jafari M. Sami Hagialilo S Jahani M khodabandeh A Eghbal L Gholibekian S |
| author_sort | Alimoghadam K |
| collection | DOAJ |
| description | : Osteosarcoma is the most common bone sarcoma, and the third most common malignancy in children and adolescents. Before 1970, amputation was the sole treatment. Eighty percent of patients died from metastatic diseases, most commonly in the lungs. Over the past three decades, effective neoadjuvant (preoperative) and adjuvant (postoperative) chemotherapy protocols have improved the ability to perform limb salvage resections, disease free survival and overall survival rates."nPatients and Methods: The study was conducted on 28 patients (15 male and 13 female) whose diagnoses were confirmed by excisional biopsy without any proof of metastasis in clinical and radiological assessments from September 2001 to November 2002. All patients were treated with three-drug regimen consisting of Adriamycin, Ifosfamide and Cisplatin. The neoadjuvant chemotherapy was administered in three courses. The first course, Ifosfamide (2gr/IV) and Adriamycin (75mg/m², IV infusion) were given on the first day and Ifosfamide (1.5 gr/m² by continuous infusion) alone for 6 days. The second course consisted of Adriamycin (75mg/m², IV infusion) and Cisplatin (100mg/m², IV infusion) for one day. The third course was the same as the first. After surgery, all patients received adjuvant therapy similar to the neoadjuvant protocol mentioned above. Limb salvage was the most common surgical method. The treatment outcome particularly depended on the percentage of tumor necrosis. Overall and disease-free survival were also measured."nResults: According to the tumor necrosis percentage, the tumor response to chemotherapy was classified from good to poor response. In this study, 63.6% of patients showed good response and 36.4% indicated poor or no response to chemotherapy. The tumor necrosis percentage was significantly correlated with age≤ 20 years (P= 0.01), tumor size ≤84 cm³ (P= 0.03) and the site of tumors in femurs (P= 0.03). The average follow-up time was 132 days, ranging from 15 to 618 days. The first year survival rate was 100%, and the disease-free survival (DFS) was 70.8% for the same time period. Disease-free survival was significantly correlated with the chemotherapy response (P= 0.03), which was 100% in the good response group in the first year."nConclusion: Although we had utilized bone grafts for substantially resected bones, local relapses were remarkably low (2 cases), so we suggest that this surgical method can be a proper alternative treatment for different types of expensive prosthesis in countries with low socioeconomic status. |
| first_indexed | 2024-03-12T19:05:46Z |
| format | Article |
| id | doaj.art-f7e8c55af93540888b412d61a521803c |
| institution | Directory Open Access Journal |
| issn | 2008-3009 2008-2207 |
| language | English |
| last_indexed | 2024-03-12T19:05:46Z |
| publishDate | 2004-07-01 |
| publisher | Tehran University of Medical Sciences |
| record_format | Article |
| series | International Journal of Hematology-Oncology and Stem Cell Research |
| spelling | doaj.art-f7e8c55af93540888b412d61a521803c2023-08-02T06:18:09ZengTehran University of Medical SciencesInternational Journal of Hematology-Oncology and Stem Cell Research2008-30092008-22072004-07-01111215Neoadjuvant and Adjuvant Chemotherapy in Osteosarcoma (The Experience of HORC in the Shariati Hospital)Alimoghadam KGhavamzadeh AJafari M.Sami Hagialilo SJahani Mkhodabandeh AEghbal LGholibekian S: Osteosarcoma is the most common bone sarcoma, and the third most common malignancy in children and adolescents. Before 1970, amputation was the sole treatment. Eighty percent of patients died from metastatic diseases, most commonly in the lungs. Over the past three decades, effective neoadjuvant (preoperative) and adjuvant (postoperative) chemotherapy protocols have improved the ability to perform limb salvage resections, disease free survival and overall survival rates."nPatients and Methods: The study was conducted on 28 patients (15 male and 13 female) whose diagnoses were confirmed by excisional biopsy without any proof of metastasis in clinical and radiological assessments from September 2001 to November 2002. All patients were treated with three-drug regimen consisting of Adriamycin, Ifosfamide and Cisplatin. The neoadjuvant chemotherapy was administered in three courses. The first course, Ifosfamide (2gr/IV) and Adriamycin (75mg/m², IV infusion) were given on the first day and Ifosfamide (1.5 gr/m² by continuous infusion) alone for 6 days. The second course consisted of Adriamycin (75mg/m², IV infusion) and Cisplatin (100mg/m², IV infusion) for one day. The third course was the same as the first. After surgery, all patients received adjuvant therapy similar to the neoadjuvant protocol mentioned above. Limb salvage was the most common surgical method. The treatment outcome particularly depended on the percentage of tumor necrosis. Overall and disease-free survival were also measured."nResults: According to the tumor necrosis percentage, the tumor response to chemotherapy was classified from good to poor response. In this study, 63.6% of patients showed good response and 36.4% indicated poor or no response to chemotherapy. The tumor necrosis percentage was significantly correlated with age≤ 20 years (P= 0.01), tumor size ≤84 cm³ (P= 0.03) and the site of tumors in femurs (P= 0.03). The average follow-up time was 132 days, ranging from 15 to 618 days. The first year survival rate was 100%, and the disease-free survival (DFS) was 70.8% for the same time period. Disease-free survival was significantly correlated with the chemotherapy response (P= 0.03), which was 100% in the good response group in the first year."nConclusion: Although we had utilized bone grafts for substantially resected bones, local relapses were remarkably low (2 cases), so we suggest that this surgical method can be a proper alternative treatment for different types of expensive prosthesis in countries with low socioeconomic status.http://journals.tums.ac.ir/PdfMed.aspx?pdf_med=/upload_files/pdf/4479.pdf&manuscript_id=4479 Neoadjuvant chemotherapy |
| spellingShingle | Alimoghadam K Ghavamzadeh A Jafari M. Sami Hagialilo S Jahani M khodabandeh A Eghbal L Gholibekian S Neoadjuvant and Adjuvant Chemotherapy in Osteosarcoma (The Experience of HORC in the Shariati Hospital) International Journal of Hematology-Oncology and Stem Cell Research Neoadjuvant chemotherapy |
| title | Neoadjuvant and Adjuvant Chemotherapy in Osteosarcoma (The Experience of HORC in the Shariati Hospital) |
| title_full | Neoadjuvant and Adjuvant Chemotherapy in Osteosarcoma (The Experience of HORC in the Shariati Hospital) |
| title_fullStr | Neoadjuvant and Adjuvant Chemotherapy in Osteosarcoma (The Experience of HORC in the Shariati Hospital) |
| title_full_unstemmed | Neoadjuvant and Adjuvant Chemotherapy in Osteosarcoma (The Experience of HORC in the Shariati Hospital) |
| title_short | Neoadjuvant and Adjuvant Chemotherapy in Osteosarcoma (The Experience of HORC in the Shariati Hospital) |
| title_sort | neoadjuvant and adjuvant chemotherapy in osteosarcoma the experience of horc in the shariati hospital |
| topic | Neoadjuvant chemotherapy |
| url | http://journals.tums.ac.ir/PdfMed.aspx?pdf_med=/upload_files/pdf/4479.pdf&manuscript_id=4479 |
| work_keys_str_mv | AT alimoghadamk neoadjuvantandadjuvantchemotherapyinosteosarcomatheexperienceofhorcintheshariatihospital AT ghavamzadeha neoadjuvantandadjuvantchemotherapyinosteosarcomatheexperienceofhorcintheshariatihospital AT jafarim neoadjuvantandadjuvantchemotherapyinosteosarcomatheexperienceofhorcintheshariatihospital AT samihagialilos neoadjuvantandadjuvantchemotherapyinosteosarcomatheexperienceofhorcintheshariatihospital AT jahanim neoadjuvantandadjuvantchemotherapyinosteosarcomatheexperienceofhorcintheshariatihospital AT khodabandeha neoadjuvantandadjuvantchemotherapyinosteosarcomatheexperienceofhorcintheshariatihospital AT eghball neoadjuvantandadjuvantchemotherapyinosteosarcomatheexperienceofhorcintheshariatihospital AT gholibekians neoadjuvantandadjuvantchemotherapyinosteosarcomatheexperienceofhorcintheshariatihospital |